Ezetimibe; more than a low density lipoprotein cholesterol lowering drug? an update after 4 years

Current Vascular Pharmacology

Volumn 9, Issue 1, 2011, Pages 62-86

  Lioudaki, Eirini ^a,b   Ganotakis, Emmanuel S ^b   Mikhailidis, Dimitri P ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF CRETE   (Greece)

Author keywords

C reactive protein; Endothelial function; Ezetimibe; Insulin sensitivity; Pleiotropic; Statin

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADIPOCYTOKINE; APOLIPOPROTEIN B; APOLIPOPROTEIN E; ATORVASTATIN; C REACTIVE PROTEIN; COLESEVELAM; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; KEXIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MUSCLE ENZYME; NICOTINIC ACID; PRAVASTATIN; PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9; REACTIVE OXYGEN METABOLITE; RIMONABANT; ROSUVASTATIN; SIMVASTATIN; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG;

AORTA STENOSIS; ARTERY INTIMA; ATHEROSCLEROSIS; CANCER RISK; CARCINOGENESIS; CARDIOVASCULAR RISK; CHILD; CHOLELITHIASIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL EVALUATION; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; FAMILIAL HYPERCHOLESTEROLEMIA; GLUCOSE METABOLISM; HAIR GROWTH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; IMMUNOMODULATION; INSULIN RESISTANCE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIPID PEROXIDATION; LIVER FUNCTION TEST; LIVER PROTECTION; LIVER TRANSPLANTATION; MONOTHERAPY; NONALCOHOLIC FATTY LIVER; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SITOSTEROLEMIA; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; TREATMENT RESPONSE;

ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; AZETIDINES; CHOLESTEROL, LDL; HUMANS; TREATMENT OUTCOME;

EID: 78650927720     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016111793744760     Document Type: Review

References (249)

1. Mikhailidis DP, Wierzbicki AS, Daskalopoulou SS, et al. The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel. Curr Med Res Opin 2005; 2: 959-69.
2. Davis HR, Jr., Basso F, Hoos LM, et al. Cholesterol homeostasis by the intestine: lessons from Niemann-Pick C1 Like 1 [NPC1L1). Atheroscler Suppl 2008; 9: 77-81.
3. Miura S, Saku K. Ezetimibe, a selective inhibitor of the transport of cholesterol. Intern Med 2008; 47: 1165-70.
4. Daskalopoulou SS, Mikhailidis DP. Reaching goal in hypercholes-terolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. Curr Med Res Opin 2006; 22: 511-28.
5. Mikhailidis DP, Sibbring GC, Ballantyne CM, et al. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin 2007; 23: 2009-26.
6. Athyros VG, Tziomalos K, Kakafika AI, et al. Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients. Am J Cardiol 2008; 101: 483-5.
7. Gazi IF, Mikhailidis DP. Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview. Expert Opin Ther Targets 2006; 10: 851-66.
8. Sampalis JS, Bissonnette S, Habib R, Boukas S. Reduction in estimated risk for coronary artery disease after use of ezetimibe with a statin. Ann Pharmacother 2007; 41: 1345-51.
9. Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358: 1431-43.
10. O'Keefe JH, Bybee KA, Lavie CJ. Intensive lipid intervention in the post-ENHANCE era. Mayo Clin Proc 2008; 83: 867-9.
11. Hamilton-Craig IR. After ENHANCE: the cholesterol hypothesis is alive and well. Med J Aust 2008; 189: 303-4.
12. Smilde TJ, van Wissen S, Wollersheim H, et al. Effect of aggressive vs. conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001; 357: 577-81.
13. van Wissen S, Smilde TJ, Trip MD, et al. Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia. Am J Cardiol 2005; 95: 264-6.
14. Fleg JL, Mete M, Howard BV, et al. Effect of statins alone vs. statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol 2008; 52: 2198-205.
15. Meaney A, Ceballos G, Asbun J, et al. The VYtorin on Carotid intima-media thickness and overall arterial rigidity (VYCTOR) study. J Clin Pharmacol 2009; 49: 838-47.
16. Brown BG, Taylor AJ. Does ENHANCE diminish confidence in lowering LDL or in ezetimibe? N Engl J Med 2008; 358: 1504-7.
17. Fee WH Jr. The ENHANCE trial. Cleve Clin J Med 2008; 75: 763.
18. Porat G. The ENHANCE trial. Cleve Clin J Med 2008; 75: 763-767.
19. Stein EA. After ENHANCE: is more LDL cholesterol lowering even better? Clin Chem 2008; 54: 940-2.
20. Taylor AJ. Given the ENHANCE trial results, ezetimibe is still unproven. Cleve Clin J Med 2008; 75: 497-8, 502, 505-6.
21. Drazen JM, Jarcho JA, Morrissey S, Curfman GD. Cholesterol lowering and ezetimibe. N Engl J Med 2008; 358: 1507-8.
22. Davidson MH. Is ezetimibe/simvastatin no better than simvastatin alone? Lessons learned and clinical implications. Cleve Clin J Med 2008; 75: 479-82, 486-8, 490-1.
23. Toutouzas P, Richter D. Carotid intima-media thickness (cIMT): a useful clinic tool or research luxury? Another view of the ENHANCE trial. Angiology 2008; 59: 77S-9S.
24. Cannon CP, Giugliano RP, Blazing MA, et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin vs. simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 2008; 156: 826-32.
25. Musunuru K, Blumenthal RS. The implications of the ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression trial: a return to first principles. Clin Cardiol 2008; 31: 288-90.
26. Rossebo AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008; 359: 1343-56.
27. Holme I, Boman K, Brudi P, et al. Observed and predicted reduction of ischemic cardiovascular events in the simvastatin and ezetimibe in aortic stenosis trial. Am J Cardiol 2010; DOI: 10.1016/j.amjcard.2010.01.363.
28. Nakagami H, Osako MK, Takami Y, et al. Vascular protective effects of ezetimibe in ApoE-deficient mice. Atherosclerosis 2009; 203: 51-8.
29. Kuhlencordt PJ, Padmapriya P, Rutzel S, et al. Ezetimibe potently reduces vascular inflammation and arteriosclerosis in eNOS-deficient ApoE ko mice. Atherosclerosis 2009; 202: 48-57.
30. Dietrich T, Hucko T, Bourayou R, et al. High resolution magnetic resonance imaging in atherosclerotic mice treated with ezetimibe. Int J Cardiovasc Imaging 2009; 25(8): 827-36.
31. Gomez-Garre D, Munoz-Pacheco P, Gonzalez-Rubio ML, et al. Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipid-lowering effect. Br J Pharmacol 2009; 156: 1218-27.
32. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-39.
33. Pandor A, Ara RM, Tumur I, et al. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. J Intern Med 2009; 265: 568-80.
34. Gazi IF, Daskalopoulou SS, Nair DR, Mikhailidis DP. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Curr Med Res Opin 2007; 23: 2183-92.
35. Yamaoka-Tojo M, Tojo T, Kosugi R, et al. Effects of ezetimibe add-on therapy for high-risk patients with dyslipidemia. Lipids Health Dis 2009; 8: 41.
36. Venero CV, Venero JV, Seip RL, Thompson PD. Effectiveness of thrice weekly ezetimibe. Am J Cardiol 2008; 102: 1205-6.
37. Fras Z, Mikhailidis DP. Statin plus ezetimibe treatment in clinical practice: the SI-SPECT (Slovenia (SI) Statin Plus Ezetimibe in Cholesterol Treatment) monitoring of clinical practice study. Curr Med Res Opin 2008; 24: 2467-76.
38. Eichner JE, Kuller LH, Orchard TJ, et al. Relation of apolipoprotein E phenotype to myocardial infarction and mortality from coronary artery disease. Am J Cardiol 1993; 71: 160-5.
39. Bocksch L, Stephens T, Lucas A, Singh B. Apolipoprotein E: possible therapeutic target for atherosclerosis. Curr Drug Targets Cardiovasc Haematol Disord 2001; 1: 93-106.
40. Wilson PW, Myers RH, Larson MG, et al. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. JAMA 1994; 272: 1666-71.
41. Mark L, Dani G, Fazekas O, et al. Effects of ezetimibe on lipids and lipoproteins in patients with hypercholesterolemia and different apolipoprotein E genotypes. Curr Med Res Opin 2007; 23: 1541-8.
42. Teng B, Thompson GR, Sniderman AD, et al. Composition and distribution of low density lipoprotein fractions in hyperapobe-talipoproteinemia, normolipidemia, and familial hypercholes-terolemia. Proc Natl Acad Sci USA 1983; 80: 6662-6.
43. Austin MA, Breslow JL, Hennekens CH, et al. Low-density lipo-protein subclass patterns and risk of myocardial infarction. JAMA 1988; 260: 1917-21.
44. Kalogirou M, Tsimihodimos V, Gazi I, et al. Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr Med Res Opin 2007; 23: 1169-76.
45. Tribble DL, Farnier M, Macdonell G, et al. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipide-mia. Metabolism 2008; 57: 796-801.
46. Kolovou GD, Anagnostopoulou KK, Daskalopoulou SS, et al. Clinical relevance of postprandial lipaemia. Curr Med Chem 2005; 12: 1931-45.
47. Masuda D, Nakagawa-Toyama Y, Nakatani K, et al. Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia. Eur J Clin Invest 2009; 39: 689-98.
48. Brudi P, Reckless JP, Henry DP, et al. Efficacy of ezetimibe/simvastatin 10/40 mg compared to doubling the dose of low-, medium- and high-potency statin monotherapy in patients with a recent coronary event. Cardiology 2009; 113: 89-97.
49. Reckless JP, Henry P, Pomykaj T, et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study. Int J Clin Pract 2008; 62: 539-54.
50. Bays H, Sapre A, Taggart W, et al. Long-term (48-week) safety of ezetimibe 10 mg/day coadministered with simvastatin compared to simvastatin alone in patients with primary hypercholesterolemia. Curr Med Res Opin 2008; 24: 2953-66.
51. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholes-terolemia. J Am Coll Cardiol 2002; 40: 2125-34.
52. Strony J, Yang B, Hanson ME, Veltri EP. Long-term safety and tolerability of ezetimibe coadministered with simvastatin in hyper-cholesterolemic patients: a randomized, 12-month double-blind extension study. Curr Med Res Opin 2008; 24: 3149-57.
53. Strony J, Hoffman R, Hanson M, Veltri E. Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: results from two open-label extension studies in hypercholesterolemic patients. Clin Ther 2008; 30: 2280-97.
54. Chenot F, Montant PF, Marcovitch O, et al. Co-administration of ezetimibe and simvastatin in acute myocardial infarction. Eur J Clin Invest 2007; 37: 357-63.
55. Farnier M, Averna M, Missault L, et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study. Int J Clin Pract 2009; 63: 547-59.
56. Hildemann SK, Barho C, Karmann B, et al. Dual cholesterol inhibition with ezetimibe/simvastatin in pre-treated hypercholestero-laemic patients with coronary heart disease or diabetes mellitus: prospective observational cohort studies in clinical practice. Curr Med Res Opin 2007; 23: 713-9.
57. Hildemann SK, Barho C, Karmann B, et al. Sustained effects in hypercholesterolaemic patients on combined simvastatin/ezetimibe treatment: observational cohort study in clinical practice. Curr Med Res Opin 2008; 24: 2777-84.
58. Ose L, Reyes R, Johnson-Levonas AO, et al. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques. Clin Ther 2007; 29: 2419-32.
59. Farnier M, Perevozskaya I, Taggart WV, et al. VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate. J Lipid Res 2008; 49: 2641-7.
60. Conard SE, Bays HE, Leiter LA, et al. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) vs. uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease. Am J Cardiol 2008; 102: 1489-94.
61. Leiter LA, Bays H, Conard S, et al. Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease. Am J Cardiol 2008; 102: 1495-501.
62. Zieve F, Wenger NK, Ben-Yehuda O, et al. Safety and efficacy of ezetimibe added to atorvastatin vs. up titration of atorvastatin to 40 mg in Patients > or = 65 years of age (from the ZETia in the ELD-erly [ZETELD] study). Am J Cardiol 2010; 105: 656-63.
63. Alvarez-Sala LA, Cachofeiro V, Masana L, et al. Effects of fluvas-tatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and in-flammatory parameters in patients with primary hypercholes-terolemia: a 12-week, multicenter, randomized, open-label, parallel-group study. Clin Ther 2008; 30: 84-97.
64. Dagli N, Yavuzkir M, Karaca I. The effects of high dose pravastatin and low dose pravastatin and ezetimibe combination therapy on lipid, glucose metabolism and inflammation. Inflammation 2007; 30: 230-5.
65. Ballantyne CM, Weiss R, Moccetti T, et al. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol 2007; 99: 673-80.
66. Farnier M, Roth E, Gil-Extremera B, et al. Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia. Am Heart J 2007; 153: 335 e18.
67. Jelesoff NE, Ballantyne CM, Xydakis AM, et al. Effectiveness and tolerability of adding ezetimibe to niacin-based regimens for treatment of primary hyperlipidemia. Endocr Pract 2006; 12: 159-64.
68. Guyton JR, Brown BG, Fazio S, et al. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extendedrelease niacin in patients with type IIa or type IIb hyperlipidemia. J Am Coll Cardiol 2008; 51: 1564-72.
69. Kosoglou T, Statkevich P, Johnson-Levonas AO, et al. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 2005; 44: 467-94.
70. Bays H, Rhyne J, Abby S, et al. Lipid-lowering effects of colesevelam HCl in combination with ezetimibe. Curr Med Res Opin 2006; 22: 2191-200.
71. Knopp RH, Tsunehara C, Retzlaff BM, et al. Lipoprotein effects of combined ezetimibe and colesevelam hydrochloride vs. ezetimibe alone in hypercholesterolemic subjects: a pilot study. Metabolism 2006; 55: 1697-703.
72. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999; 341: 498-511.
73. Rivers SM, Kane MP, Busch RS, et al. Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance. Endocr Pract 2007; 13: 11-6.
74. Florentin M, Kostapanos MS, Nakou ES, et al. Efficacy and safety of ezetimibe plus orlistat or rimonabant in statin-intolerant non-diabetic overweight/obese patients with dyslipidemia. J Cardiovasc Pharmacol Ther 2009; 14: 274-82.
75. Tremblay AJ, Lamarche B, Cohn JS, et al. Effect of ezetimibe on the in vivo kinetics of apoB-48 and apoB-100 in men with primary hypercholesterolemia. Arterioscler Thromb Vasc Biol 2006; 26: 1101-6.
76. Tremblay AJ, Lamarche B, Hogue JC, Couture P. Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia. J Lipid Res 2009; 50: 1463-71.
77. Gouni-Berthold I, Berthold HK, Gylling H, et al. Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase gene expression: a randomized trial in healthy men. Atherosclerosis 2008; 198: 198-207.
78. Tselepis AD, Dentan C, Karabina SA, et al. PAF-degrading acetyl-hydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme. Arterioscler Thromb Vasc Biol 1995; 15: 1764-73.
79. Saougos VG, Tambaki AP, Kalogirou M, et al. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler Thromb Vasc Biol 2007; 27: 2236-43.
80. Hussein O, Minasian L, Itzkovich Y, et al. Ezetimibe's effect on platelet aggregation and LDL tendency to peroxidation in hyper-cholesterolaemia as monotherapy or in addition to simvastatin. Br J Clin Pharmacol 2008; 65: 637-45.
81. Aviram M, Rosenblat M. Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences. Curr Opin Lipi-dol 2005; 16: 393-9.
82. de Graaf J, Hendriks JC, Demacker PN, Stalenhoef AF. Identification of multiple dense LDL subfractions with enhanced susceptibility to in vitro oxidation among hypertriglyceridemic subjects. Normalization after clofibrate treatment. Arterioscler Thromb 1993; 13: 712-9.
83. Davignon J, Dubuc G. Statins and ezetimibe modulate plasma proprotein convertase subtilisin Kexin-9 (PCSK9) levels. Trans Am Clin Climatol Assoc 2009; 120: 163-73.
84. Dubuc G, Tremblay M, Pare G, et al. A new method for measurement of total plasma PSCK9 - clinical applications. J Lipid Res 2010; 51: 140-9.
85. Tseng KH. Standards of medical care in diabetes--2006: response to the American Diabetes Association. Diabetes Care 2006; 29: 2563-4.
86. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-52.
87. Goldberg RB, Guyton JR, Mazzone T, et al. Ezetimibe/simvastatin vs. atorvastatin in patients with type 2 diabetes mellitus and hyper-cholesterolemia: the VYTAL study. Mayo Clin Proc 2006; 81: 1579-88.
88. Tomassini JE, Mazzone T, Goldberg RB, et al. Effect of ezetimibe/simvastatin compared with atorvastatin on lipoprotein subclasses in patients with type 2 diabetes and hypercholesterolaemia. Diabetes Obes Metab 2009; 11: 855-64.
89. Hajer GR, Dallinga-Thie GM, van Vark-van der Zee LC, Visseren FL. The effect of statin alone or in combination with ezetimibe on postprandial lipoprotein composition in obese metabolic syndrome patients. Atherosclerosis 2009; 202: 216-24.
90. Hajer GR, Dallinga-Thie GM, van Vark-van der Zee LC, et al. Lipid-lowering therapy does not affect the postprandial drop in high density lipoprotein-cholesterol (HDL-c) plasma levels in obese men with metabolic syndrome: a randomized double blind crossover trial. Clin Endocrinol (Oxf) 2008; 69: 870-7.
91. Robinson JG, Ballantyne CM, Grundy SM, et al. Lipid-altering efficacy and safety of ezetimibe/simvastatin vs. atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). Am J Cardiol 2009; 103: 1694-702.
92. Migdalis I, Efthimiadis A, Pappas S, et al. Clinical experience with ezetimibe/simvastatin in a Mediterranean population. Curr Med Res Opin 2009; 25: 2571-6.
93. Derosa G, D'Angelo A, Franzetti IG, et al. Efficacy and safety of ezetimibe/simvastatin association on non-diabetic and diabetic patients with polygenic hypercholesterolemia or combined hyperlipi-demia and previously intolerant to standard statin treatment. J Clin Pharm Ther 2009; 34: 267-76.
94. Constance C, Westphal S, Chung N, et al. Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2007; 9: 575-84.
95. Winkler K, Schewe T, Putz G, et al. Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles. Eur J Clin Invest 2009; 39: 463-70.
96. Feldman T, Ose L, Shah A, et al. Efficacy and safety of ezetimibe/simvastatin vs. simvastatin monotherapy in hypercholes-terolemic patients with metabolic syndrome. Metab Syndr Relat Disord 2007; 5: 13-21.
97. Gil-Extremera B, Mendez G, Zakson M, et al. Efficacy and safety of ezetimibe/simvastatin co-administered with fenofibrate in mixed hyperlipidemic patients with metabolic syndrome. Metab Syndr Relat Disord 2007; 5: 305-14.
98. Koenig W, Sund M, Frohlich M, et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237-42.
99. Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999; 100: 230-5.
100. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-207.
101. Pearson T, Ballantyne C, Sisk C, et al. Comparison of effects of ezetimibe/simvastatin vs. simvastatin vs. atorvastatin in reducing Creactive protein and low-density lipoprotein cholesterol levels. Am J Cardiol 2007; 99: 1706-13.
102. Settergren M, Bohm F, Ryden L, Pernow J. Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease. Eur Heart J 2008; 29: 1753-60.
103. Settergren M, Bohm F, Ryden L et al. Lipid lowering vs. pleiotropic effects of statins on skin microvascular function in patients with dysglycaemia and coronary artery disease. J Intern Med 2009; 266: 492-8.
104. Fichtlscherer S, Schmidt-Lucke C, Bojunga S, et al. Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for 'pleiotropic' functions of statin therapy. Eur Heart J 2006; 27: 1182-90.
105. Pearson TA, Ballantyne CM, Veltri E, et al. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy. Am J Cardiol 2009; 103: 369-74.
106. Maki-Petaja KM, Booth AD, Hall FC, et al. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll Cardiol 2007; 50: 852-8.
107. Araujo DB, Bertolami MC, Ferreira WP, et al. Pleiotropic effects with equivalent LDL-cholesterol reduction: comparative study between simvastatin and simvastatin/ezetimibe co-administration. J Cardiovasc Pharmacol 2010; 55: 1-5.
108. Efrati S, Averbukh M, Dishy V, et al. The effect of simvastatin, ezetimibe and their combination on the lipid profile, arterial stiffness and inflammatory markers. Eur J Clin Pharmacol 2007; 63: 113-21.
109. Castellote J, Ariza J, Rota R, et al. Serious drug-induced liver disease secondary to ezetimibe. World J Gastroenterol 2008; 14: 5098-9.
110. Kashani A, Sallam T, Bheemreddy S, et al. Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials. Am J Cardiol 2008; 101: 1606-13.
111. Meas T, Cimadevilla C, Timsit J, et al. Elevation of CKP induced by ezetimibe in monotherapy: report on two cases. Diabetes Metab 2006; 32: 364-6.
112. Caglar K, Yilmaz MI, Sonmez A, et al. ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease. Kidney Int 2006; 70: 781-7.
113. Yilmaz MI, Saglam M, Caglar K, et al. The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric di-methylarginine. Am J Kidney Dis 2006; 47: 42-50.
114. Fliser D, Kronenberg F, Kielstein JT, et al. Asymmetric dimethy-larginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 2005; 16: 2456-61.
115. Matsuguma K, Ueda S, Yamagishi S, et al. Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hyper-tension in chronic kidney disease. J Am Soc Nephrol 2006; 17: 2176-83.
116. Matsumoto Y, Ueda S, Yamagishi S, et al. Dimethylarginine di-methylaminohydrolase prevents progression of renal dysfunction by inhibiting loss of peritubular capillaries and tubulointerstitial fibrosis in a rat model of chronic kidney disease. J Am Soc Nephrol 2007; 18: 1525-33.
117. Shepherd J, Kastelein JJ, Bittner V, et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol 2008; 51: 1448-54.
118. Athyros VG, Mikhailidis DP, Liberopoulos EN, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant 2007; 22: 118-27.
119. Lu TM, Ding YA, Leu HB, et al. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercho-lesterolemia. Am J Cardiol 2004; 94: 157-61.
120. Oguz A, Uzunlulu M. Short term fluvastatin treatment lowers serum asymmetric dimethylarginine levels in patients with metabolic syndrome. Int Heart J 2008; 49: 303-11.
121. Panichi V, Mantuano E, Paoletti S, et al. Effect of simvastatin on plasma asymmetric dimethylarginine concentration in patients with chronic kidney disease. J Nephrol 2008; 21: 38-44.
122. Paiva H, Laakso J, Lehtimaki T, et al. Effect of high-dose statin treatment on plasma concentrations of endogenous nitric oxide syn-thase inhibitors. J Cardiovasc Pharmacol 2003; 41: 219-22.
123. Nakamura T, Sato E, Fujiwara N, et al. Ezetimibe decreases serum levels of asymmetric dimethylarginine (ADMA) and ameliorates renal injury in non-diabetic chronic kidney disease patients in a cholesterol-independent manner. Pharmacol Res 2009; 60: 525-8.
124. Yagi S, Akaike M, Aihara KI, et al. Ezetimibe ameliorates meta-bolic disorders and microalbuminuria in patients with hypercholes-terolemia. J Atheroscler Thromb 2010; 17: 173-80.
125. Peto R, Emberson J, Landray M, et al. Analyses of cancer data from three ezetimibe trials. N Engl J Med 2008; 359: 1357-66.
126. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-9.
127. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002; 360: 1623-30.
128. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.
129. Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int Suppl 2003: S207-10.
130. Drazen JM, D'Agostino RB, Ware JH, et al. Ezetimibe and cancer-an uncertain association. N Engl J Med 2008; 359: 1398-9.
131. Nissen SE. Analyses of cancer data from three ezetimibe trials. N Engl J Med 2009; 360: 86-7.
132. Alsheikh-Ali AA, Karas RH. EZE and the combination of EZE/simvastatin, and risk of cancer: A post-marketing analysis. J Clin Lipidol 2009; 3: 138-42.
133. Halleck M, Davis HR, Kirschmeier P, et al. An assessment of the carcinogenic potential of ezetimibe using non-clinical data in a weight-of-evidence approach. Toxicology 2009; 258: 116-30.
134. Miettinen TA, Gylling H. Effect of statins on non-cholesterol sterol levels: implications for use of plant stanols and sterols. Am J Cardiol 2005; 96: 40D-46D.
135. Miettinen TA, Strandberg TE, Gylling H. Non-cholesterol sterols and cholesterol lowering by long-term simvastatin treatment in coronary patients: relation to basal serum cholestanol. Arterioscler Thromb Vasc Biol 2000; 20: 1340-6.
136. Hidaka H, Kojima H, Kawabata T, et al. Effects of an HMG-CoA reductase inhibitor, pravastatin, and bile sequestering resin, cholestyramine, on plasma plant sterol levels in hypercholesterolemic subjects. J Atheroscler Thromb 1995; 2: 60-5.
137. Sudhop T, Reber M, Tribble D et al. Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men. J Lipid Res 2009; 50: 2117-23.
138. Hiramitsu S, Ishiguro Y, Matsuyama H, et al. The effects of ezetimibe on surrogate markers of cholesterol absorption and synthesis in Japanese patients with dyslipidemia. J Atheroscler Thromb 2010; 17: 106-14.
139. Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 2005; 96: 1221-32.
140. Sehayek E, Duncan EM, Lutjohann D, et al. Loci on chromosomes 14 and 2, distinct from ABCG5/ABCG8, regulate plasma plant sterol levels in a C57BL/6J x CASA/Rk intercross. Proc Natl Acad Sci USA 2002; 99: 16215-9.
141. Sehayek E, Hazen SL. Cholesterol absorption from the intestine is a major determinant of reverse cholesterol transport from peripheral tissue macrophages. Arterioscler Thromb Vasc Biol 2008; 28: 1296-7.
142. Briand F, Naik SU, Fuki I, et al. Both the Peroxisome Proliferator-Activated Receptor (PPAR) delta agonist, GW0742, and ezetimibe promote reverse cholesterol transport in mice by reducing intestinal re-absorption of HDL-derived cholesterol. Clin Transl Sci 2009; 2: 127.
143. Halcox JP, Deanfield JE. Endothelial cell function testing: how does the method help us in evaluating vascular status? Acta Paediatr Suppl 2004; 93: 48-54.
144. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation 2007; 115: 1285-95.
145. Goch A, Banach M, Mikhailidis DP, et al. Endothelial dysfunction in patients with non-complicated and complicated hypertension. Clin Exp Hypertens 2009; 31:20-30.
146. Schonbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 2004; 109: II18-26.
147. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004; 109: III39-43.
148. Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP. Endothelial function, arterial stiffness and lipid lowering drugs. Expert Opin Ther Targets 2007; 11: 1143-60.
149. Gounari P, Tousoulis D, Antoniades C, et al. Rosuvastatin but not ezetimibe improves endothelial function in patients with heart failure, by mechanisms independent of lipid lowering. Int J Cardiol 2009; 142: 87-91.
150. Liu PY, Liu YW, Lin LJ, et al. Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation 2009; 119: 131-8.
151. Ostad MA, Eggeling S, Tschentscher P, et al. Flow-mediated dilation in patients with coronary artery disease is enhanced by high dose atorvastatin compared to combined low dose atorvastatin and ezetimibe: results of the CEZAR study. Atherosclerosis 2009; 205: 227-32.
152. Ballantyne CM, Abate N, Yuan Z, et al. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) vs. atorvastatin in patients with hypercholesterolemia: the Vytorin vs. Atorvastatin (VYVA) study. Am Heart J 2005; 149: 464-73.
153. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-7.
154. Vasa M, Fichtlscherer S, Aicher A, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001; 89: E1-7.
155. Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348: 593-600.
156. Westerweel PE, Visseren FL, Hajer GR, et al. Endothelial progenitor cell levels in obese men with the metabolic syndrome and the effect of simvastatin monotherapy vs. simvastatin/ezetimibe combination therapy. Eur Heart J 2008; 29: 2808-17.
157. Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-9.
158. Day CP, James OF. Steatohepatitis: a tale of two hits? Gastroenterology 1998; 114: 842-5.
159. Labonte ED, Camarota LM, Rojas JC, et al. Reduced absorption of saturated fatty acids and resistance to diet-induced obesity and diabetes by ezetimibe-treated and Npc1l1-/- mice. Am J Physiol Gas-trointest Liver Physiol 2008; 295: G776-83.
160. Deushi M, Nomura M, Kawakami A, et al. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett 2007; 581: 5664-70.
161. Nomura M, Ishii H, Kawakami A, Yoshida M. Inhibition of hepatic Neiman-Pick C1-like 1 improves hepatic insulin resistance. Am J Physiol Endocrinol Metab 2009 [Epub ahead of print].
162. Zheng S, Hoos L, Cook J, et al. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice. Eur J Pharmacol 2008; 584: 118-24
163. Assy N, Grozovski M, Bersudsky I, et al. Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease. World J Gastroenterol 2006; 12: 4369-76.
164. Nozaki Y, Fujita K, Yoneda M, et al. Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease. J Hepatol 2009; 51: 548-56.
165. Enjoji M, Machida K, Kohjima M, et al. NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with non-alcoholic fatty liver disease. Lipids Health Dis 2010; 9: 29.
166. Jagroop IA, Kakafika AI, Mikhailidis DP. Platelets and vascular risk: an option for treatment. Curr Pharm Des 2007; 13: 1669-83.
167. Betteridge DJ, Cooper MB, Saggerson ED, et al. Platelet function in patients with hypercholesterolaemia. Eur J Clin Invest 1994; 24 (Suppl 1): 30-3.
168. Schror K, Lobel P, Steinhagen-Thiessen E. Simvastatin reduces platelet thromboxane formation and restores normal platelet sensitivity against prostacyclin in type IIa hypercholesterolemia. Eicosanoids 1989; 2: 39-45.
169. Rauch U, Osende JI, Chesebro JH, et al. Statins and cardiovascular diseases: the multiple effects of lipid-lowering therapy by statins. Atherosclerosis 2000; 153: 181-9.
170. Piorkowski M, Weikert U, Schwimmbeck PL, et al. ADP induced platelet degranulation in healthy individuals is reduced by clopidogrel after pretreatment with atorvastatin. Thromb Haemost 2004; 92: 614-20.
171. Puccetti L, Pasqui AL, Auteri A, Bruni F. Mechanisms for anti-platelet action of statins. Curr Drug Targets Cardiovasc Haematol Disord 2005; 5: 121-6.
172. Milionis HJ, Elisaf MS, Mikhailidis DP. The effects of lipid-regulating therapy on haemostatic parameters. Curr Pharm Des 2003; 9: 2425-43.
173. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. Effect of statins and aspirin alone and in combination on clinical outcome in dyslipidaemic patients with coronary heart disease. A subgroup analysis of the GREACE study. Platelets 2005; 16: 65-71.
174. Piorkowski M, Fischer S, Stellbaum C, et al. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets? J Am Coll Cardiol 2007; 49: 1035-42.
175. Malmstrom RE, Settergren M, Bohm F, et al. No effect of lipid lowering on platelet activity in patients with coronary artery disease and type 2 diabetes or impaired glucose tolerance. Thromb Haemost 2009; 101: 157-64.
176. Carey MC. Pathogenesis of gallstones. Am J Surg 1993; 165: 410-9.
177. Amigo L, Quinones V, Mardones P, et al. Impaired biliary cholesterol secretion and decreased gallstone formation in apolipoprotein E-deficient mice fed a high-cholesterol diet. Gastroenterology 2000; 118: 772-9.
178. Buhman KK, Accad M, Novak S, et al. Resistance to diet-induced hypercholesterolemia and gallstone formation in ACAT2-deficient mice. Nat Med 2000; 6: 1341-7.
179. Wang HH, Wang DQ. Reduced susceptibility to cholesterol gallstone formation in mice that do not produce apolipoprotein B48 in the intestine. Hepatology 2005; 42: 894-904.
180. Wang HH, Portincasa P, Mendez-Sanchez N, et al. Effect of ezetimibe on the prevention and dissolution of cholesterol gall-stones. Gastroenterology 2008; 134: 2101-10.
181. Zuniga S, Molina H, Azocar L, et al. Ezetimibe prevents cholesterol gallstone formation in mice. Liver Int 2008; 28: 935-47.
182. Valasek MA, Repa JJ, Quan G, et al. Inhibiting intestinal NPC1L1 activity prevents diet-induced increase in biliary cholesterol in Golden Syrian hamsters. Am J Physiol Gastrointest Liver Physiol 2008; 295: G813-22.
183. Mathur A, Walker JJ, Al-Azzawi HH, et al. Ezetimibe ameliorates cholecystosteatosis. Surgery 2007; 142: 228-33.
184. Sethi JK, Vidal-Puig AJ. Thematic review series: adipocyte biology. Adipose tissue function and plasticity orchestrate nutritional adaptation. J Lipid Res 2007; 48: 1253-62.
185. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005; 26: 439-51.
186. McTernan PG, Kusminski CM, Kumar S. Resistin. Curr Opin Lipidol 2006; 17: 170-5.
187. van Heek M, Austin TM, Farley C, et al. Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters. Diabetes 2001; 50: 1330-5.
188. Gouni-Berthold I, Berthold HK, Chamberland JP, et al. Short-term treatment with ezetimibe, simvastatin or their combination does not alter circulating adiponectin, resistin or leptin levels in healthy men. Clin Endocrinol (Oxf) 2008; 68: 536-41.
189. Florentin M, Liberopoulos EN, Tellis CC, et al. Effects of rimona-bant, as monotherapy and in combination with fenofibrate or ezetimibe, on plasma adipokine levels: a pilot study. Angiology 2009; 61: 365-71.
190. Ali A, Martin JMt. Hair growth in patients alopecia areata totalis after treatment with simvastatin and ezetimibe. J Drugs Dermatol 2010; 9: 62-4.
191. Robins DN. Case reports: alopecia universalis: hair growth following initiation of simvastatin and ezetimibe therapy. J Drugs Dermatol 2007; 6: 946-7.
192. Tungsiripat M, Aberg JA. Dyslipidemia in HIV patients. Cleve Clin J Med 2005; 72: 1113-20.
193. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunode-ficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-60.
194. Manfredi R. Management of dyslipidemia in patientswith HIV disease. Clin Microbiol Infect 2000; 6: 579-84.
195. Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003; 37: 613-27.
196. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
197. Coll B, Aragones G, Parra S, et al. Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients. AIDS 2006; 20: 1675-7.
198. Negredo E, Molto J, Puig J, et al. Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins. AIDS 2006; 20: 2159-64.
199. Bennett MT, Johns KW, Bondy GP. Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV. Lipids Health Dis 2007; 6: 15.
200. Berg-Wolf MV, Klibanov OM, Gaughan JP, Tedaldi EM. Ezetimibe combined with low-dose statin effectively lowers LDL in protease inhibitor treated patients. AIDS Patient Care STDS 2008 [Epub ahead of print].
201. Wohl DA, Waters D, Simpson RJ Jr, et al. Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy. Clin Infect Dis 2008; 47: 1105-8.
202. Chow D, Chen H, Glesby MJ, et al. Short-term ezetimibe is well tolerated and effective in combination with statin therapy to treat elevated LDL cholesterol in HIV-infected patients. AIDS 2009; 23: 2133-41.
203. Gazi IF, Liberopoulos EN, Athyros VG, et al. Statins and solid organ transplantation. Curr Pharm Des 2006; 12: 4771-83.
204. Lindenfeld J, Page RL 2nd, Zolty R, et al. Drug therapy in the heart transplant recipient: Part III: common medical problems. Circulation 2005; 111: 113-7.
205. Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003; 163: 553-64.
206. Bumgardner GL, Wilson GA, Tso PL, et al. Impact of serum lipids on long-term graft and patient survival after renal transplantation. Transplantation 1995; 60: 1418-21.
207. Kobashigawa JA, Kasiske BL. Hyperlipidemia in solid organ transplantation. Transplantation 1997; 63: 331-8.
208. Kasiske B, Cosio FG, Beto J, et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Out-comes Quality Initiative. Am J Transplant 2004; 4 (Suppl 7): 13-53.
209. Buchanan C, Smith L, Corbett J, et al. A retrospective analysis of ezetimibe treatment in renal transplant recipients. Am J Transplant 2006; 6: 770-4.
210. Chuang P, Langone AJ. Ezetimibe reduces low-density lipoprotein cholesterol (LDL-C) in renal transplant patients resistant to HMG-CoA reductase inhibitors. Am J Ther 2007; 14: 438-41.
211. Lopez V, Gutierrez C, Gutierrez E, et al. Treatment with ezetimibe in kidney transplant recipients with uncontrolled dyslipidemia. Transplant Proc 2008; 40: 2925-6.
212. Rodriguez-Ferrero ML, Anaya F. Ezetimibe in the treatment of uncontrolled hyperlipidemia in kidney transplant patients. Transplant Proc 2008; 40: 3492-5.
213. Turk TR, Voropaeva E, Kohnle M, et al. Ezetimibe treatment in hypercholesterolemic kidney transplant patients is safe and effective and reduces the decline of renal allograft function: a pilot study. Nephrol Dial Transplant 2008; 23: 369-73.
214. Yoon HE, Song JC, Hyoung BJ, et al. The efficacy and safety of ezetimibe and low-dose simvastatin as a primary treatment for dyslipidemia in renal transplant recipients. Korean J Intern Med 2009; 24: 233-7.
215. Koshman SL, Lalonde LD, Burton I, et al. Supratherapeutic response to ezetimibe administered with cyclosporine. Ann Pharmacother 2005; 39: 1561-5.
216. Bergman AJ, Burke J, Larson P, et al. Interaction of single-dose ezetimibe and steady-state cyclosporine in renal transplant patients. J Clin Pharmacol 2006; 46: 328-36.
217. Imagawa DK, Dawson S, 3rd, Holt CD, et al. Hyperlipidemia after liver transplantation: natural history and treatment with the hy-droxy-methylglutaryl-coenzyme A reductase inhibitor pravastatin. Transplantation 1996; 62: 934-42.
218. Munoz SJ. Hyperlipidemia and other coronary risk factors after orthotopic liver transplantation: pathogenesis, diagnosis, and management. Liver Transpl Surg 1995; 1: 29-38.
219. Laryea M, Watt KD, Molinari M, et al. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl 2007; 13: 1109-14.
220. Taylor PJ, Kubler PA, Lynch SV, et al. Effect of atorvastatin on cyclosporine pharmacokinetics in liver transplant recipients. Ann Pharmacother 2004; 38: 205-8.
221. Almutairi F, Peterson TC, Molinari M, et al. Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholes-terolemia. Liver Transpl 2009; 15: 504-8.
222. Moro J, Almenar L, Martinez-Dolz L, et al. Ezetimibe in heart transplantation: initial experience. Transplant Proc 2007; 39: 2389-92.
223. Crespo-Leiro MG, Paniagua MJ, Marzoa R, et al. The efficacy and safety of ezetimibe for treatment of dyslipidemia after heart transplantation. Transplant Proc 2008; 40: 3060-2.
224. Le VV, Racine N, Pelletier GB, et al. Impact of ezetimibe on cholesterol subfractions in dyslipidemic cardiac transplant recipients receiving statin therapy. Clin Transplant 2009; 23: 249-55.
225. Quarta CC, Potena L, Grigioni F, et al. Safety and efficacy of ezetimibe with low doses of simvastatin in heart transplant recipients. J Heart Lung Transplant 2008; 27: 685-8.
226. Konstandin MH, Blessing E, Doesch A, et al. Ezetimibe effectively lowers LDL-cholesterol in cardiac allograft recipients on stable statin therapy. Clin Transplant 2008; 22: 639-44.
227. Shaw SM, Chaggar P, Ritchie J, et al. The efficacy and tolerability of ezetimibe in cardiac transplant recipients taking cyclosporin. Transplantation 2009; 87: 771-5.
228. Musliner T, Cselovszky D, Sirah W, et al. Efficacy and safety of ezetimibe 40 mg vs. ezetimibe 10 mg in the treatment of patients with homozygous sitosterolaemia. Int J Clin Pract 2008; 62: 995-1000.
229. Salen G, von Bergmann K, Lutjohann D, et al. Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. Circulation 2004; 109: 966-71.
230. Lutjohann D, von Bergmann K, Sirah W, et al. Long-term efficacy and safety of ezetimibe 10 mg in patients with homozygous sitosterolemia: a 2-year, open-label extension study. Int J Clin Pract 2008; 62: 1499-510.
231. Soutar AK, Naoumova RP, Traub LM. Genetics, clinical phenotype, and molecular cell biology of autosomal recessive hypercho-lesterolemia. Arterioscler Thromb Vasc Biol 2003; 23: 1963-70.
232. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Familial hypercholesterolemia and coronary heart disease: a HuGE association review. Am J Epidemiol 2004; 160: 421-9.
233. Wiegman A, de Groot E, Hutten BA, et al. Arterial intima-media thickness in children heterozygous for familial hypercholestero-laemia. Lancet 2004; 363: 369-70.
234. Kolovou GD, Dedoussis GV, Anagnostopoulou KK et al. Management of a patient with a null low-density lipoprotein receptor mutation: a case report. Angiology 2006; 57: 729-32.
235. Pitsavos C, Skoumas I, Tousoulis D, et al. The impact of ezetimibe and high-dose of statin treatment on LDL levels in patients with heterozygous familial hypercholesterolemia. Int J Cardiol 2009; 134: 280-1.
236. Tonstad S, Joakimsen O, Stensland-Bugge E, et al. Risk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolemia and control subjects. Arterio-scler Thromb Vasc Biol 1996; 16: 984-91.
237. Aggoun Y, Bonnet D, Sidi D, et al. Arterial mechanical changes in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000; 20: 2070-5.
238. de Jongh S, Lilien MR, Bakker HD, et al. Family history of cardio-vascular events and endothelial dysfunction in children with familial hypercholesterolemia. Atherosclerosis 2002; 163: 193-7.
239. National Cholesterol Education Program (NCEP): highlights of the report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics 1992; 89: 495-501.
240. American Academy of Pediatrics. Committee on Nutrition. Cholesterol in childhood. Pediatrics 1998; 101: 141-7.
241. van der Graaf A, Cuffie-Jackson C, Vissers MN, et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J Am Coll Cardiol 2008; 52: 1421-9.
242. Clauss S, Wai KM, Kavey RE, Kuehl K. Ezetimibe treatment of pediatric patients with hypercholesterolemia. J Pediatr 2009; 154: 869-72.
243. Yeste D, Chacon P, Clemente M, et al. Ezetimibe as monotherapy in the treatment of hypercholesterolemia in children and adolescents. J Pediatr Endocrinol Metab 2009; 22: 487-92.
244. da Silva EF, Barbaro G. New options in the treatment of lipid disorders in HIV-infected patients. Open AIDS J 2009; 3: 31-7.
245. Enajat M, Teerenstra S, van Kuilenburg JT, et al. Safety of the combination of intensive cholesterol-lowering therapy with oral anticoagulation medication in elderly patients with atrial fibrillation: a randomized, double-blind, placebo-controlled study. Drugs Aging 2009; 26: 585-93.
246. Jakulj L, Vissers MN, Groen AK, et al. Baseline cholesterol absorption and the response to ezetimibe/simvastatin therapy; a posthoc analysis of the ENHANCE trial. J Lipid Res 2010; 51: 755-62.
247. Pisciotta L, Fasano T, Bellocchio A, et al. Effect of ezetimibe coadministered with statins in genotype-confirmed heterozygous FH patients. Atherosclerosis 2007; 194: e116-22.
248. Berthold HK, Laaksonen R, Lehtimaki T, et al. SREBP-1c gene polymorphism is associated with increased inhibition of cholesterol-absorption in response to ezetimibe treatment. Exp Clin Endocrinol Diabetes 2008; 116: 262-7.
249. Clarenbach JJ, Reber M, Lutjohann D, et al. The lipid-lowering effect of ezetimibe in pure vegetarians. J Lipid Res 2006; 47: 2820-4.